ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Carcinoma
Renal Cell Carcinoma
Neoplasm Metastasis
Triple Negative Breast Cancer

Melanoma trials near San Francisco, CA, USA:

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be....

Enrolling
Melanoma Stage IV
Melanoma Stage III
Drug: Binimetinib
Drug: Imatinib

Phase 2

University of California San Francisco (UCSF)
University of California San Francisco (UCSF)

San Francisco, California, United States and 1 other location

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma...

Enrolling
Uveal Melanoma
Procedure: Primary Local Therapy
Drug: Darovasertib

Phase 3

Ideaya Biosciences

Palo Alto, California, United States and 74 other locations

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Palo Alto, California, United States and 23 other locations

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question ...

Enrolling
Melanoma Stage IIIB-IV
Melanoma (Skin Cancer)
Biological: Immunotherapy (ipilimumab and nivolumab)
Biological: Immunotherapy (Pembrolizumab)

Phase 2, Phase 3

Linnaeus Therapeutics

San Francisco, California, United States and 6 other locations

ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma...

Enrolling
Advanced Melanoma
Drug: Fianlimab
Drug: Cemiplimab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Stanford, California, United States and 10 other locations

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

San Francisco, California, United States and 71 other locations

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Enrolling
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

San Francisco, California, United States and 58 other locations

The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the com...

Enrolling
Melanoma
Drug: fianlimab
Drug: cemiplimab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

San Francisco, California, United States and 100 other locations

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

Phase 3

Aura Biosciences
Aura Biosciences

Palo Alto, California, United States and 64 other locations

Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments.This study will evaluate the safety and effects of...

Active, not recruiting
Metastatic Uveal Melanoma
Metastatic Ocular Melanoma
Combination Product: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)

Phase 3

Delcath Systems

Palo Alto, California, United States and 4 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems